Skip to main content

Advertisement

ADVERTISEMENT

Obesity News

News
11/24/2021
Jolynn Tumolo
Semaglutide and sodium-glucose co-transporter-2 inhibitors reduced body weight as well as diastolic and systolic blood pressure in patients with diabetes who had comorbid obesity and/or hypertension.
Semaglutide and sodium-glucose co-transporter-2 inhibitors reduced body weight as well as diastolic and systolic blood pressure in patients with diabetes who had comorbid obesity and/or hypertension.
Semaglutide and sodium-glucose...
11/24/2021
First Report Managed Care
News
11/10/2021
Jolynn Tumolo
Authors noted the effectiveness of semaglutide in improving weight loss-related outcomes in patients with obesity, and also discussed cost challenges related to this treatment option.
Authors noted the effectiveness of semaglutide in improving weight loss-related outcomes in patients with obesity, and also discussed cost challenges related to this treatment option.
Authors noted the effectiveness...
11/10/2021
First Report Managed Care

Advertisement

News
10/25/2021
Jolynn Tumolo
“These results emphasize the chronicity of obesity and the need for treatments that can maintain and maximize weight loss," researchers wrote.
“These results emphasize the chronicity of obesity and the need for treatments that can maintain and maximize weight loss," researchers wrote.
“These results emphasize the...
10/25/2021
First Report Managed Care
News
10/18/2021
Maria Asimopoulos
Researchers noted that body mass index “should always be assessed in the management of COVID-19 patients and special attention should be given to patients with obesity.”
Researchers noted that body mass index “should always be assessed in the management of COVID-19 patients and special attention should be given to patients with obesity.”
Researchers noted that body mass...
10/18/2021
First Report Managed Care
News
10/08/2021
Maria Asimopoulos
Patients with obesity experienced greater reductions in appetite, food consumption, and body weight while receiving once-weekly subcutaneous semaglutide 2.4 mg in comparison to placebo.
Patients with obesity experienced greater reductions in appetite, food consumption, and body weight while receiving once-weekly subcutaneous semaglutide 2.4 mg in comparison to placebo.
Patients with obesity...
10/08/2021
First Report Managed Care

Advertisement

News
08/06/2021
Jolynn Tumolo
Social determinants of health increase the likelihood patients will develop postoperative complications after undergoing vertical sleeve gastrectomy, study findings show.
Social determinants of health increase the likelihood patients will develop postoperative complications after undergoing vertical sleeve gastrectomy, study findings show.
Social determinants of health...
08/06/2021
First Report Managed Care
News
08/03/2021
Edan Stanley
Researchers of a recent study sought to better understand the benefits of time-restricted eating on weight loss and metabolic risk markers in patients with overweight and obesity in a randomized clinical trial.
Researchers of a recent study sought to better understand the benefits of time-restricted eating on weight loss and metabolic risk markers in patients with overweight and obesity in a randomized clinical trial.
Researchers of a recent study...
08/03/2021
First Report Managed Care
News
07/07/2021
Edan Stanley
“Understanding the predictors of weight loss with lifestyle interventions can help to ascertain the probable outcomes of individuals with obesity who undergo such interventions,” explain researchers of a study.
“Understanding the predictors of weight loss with lifestyle interventions can help to ascertain the probable outcomes of individuals with obesity who undergo such interventions,” explain researchers of a study.
“Understanding the predictors of...
07/07/2021
First Report Managed Care

Advertisement

News
04/03/2021
Maria Asimopoulos
A meta-analysis indicated that the combination of polyglucosamine supplementation with behavioral interventions effectively reduced weight and body mass index in patients with obesity, which could minimize the risk of chronic disease in this...
A meta-analysis indicated that the combination of polyglucosamine supplementation with behavioral interventions effectively reduced weight and body mass index in patients with obesity, which could minimize the risk of chronic disease in this...
A meta-analysis indicated that...
04/03/2021
First Report Managed Care
News
03/03/2021
Maria Asimopoulos
Different treatment approaches including lifestyle, diet, and exercise changes; medications; and bariatric surgery, produce variable weight loss in patients with obesity.
Different treatment approaches including lifestyle, diet, and exercise changes; medications; and bariatric surgery, produce variable weight loss in patients with obesity.
Different treatment approaches...
03/03/2021
First Report Managed Care

Advertisement